The FDA has approved Kapidex (dexlansoprazole, fromTakeda) delayed release capsules for the treatment of heartburn associated withsymptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing oferosive esophagitis (EE), and the maintenance of healed EE. The approval isbased on two identically designed, double-blind, eight-week, randomized,controlled trials in which Kapidex (60mg) produced high overall healing ratesfor EE at week eight when compared to lansoprazole 30mg and was generallywell-tolerated.
Kapidex is a proton pump inhibitor (PPI) that utilizes aDual Delayed Release (DDR) formulation designed to provide two separate releasesof medication. It will be available in 30mg and 60mg dosagestrengths.
For more information call (877) 825-3327 or visitwww.kapidex.com.